Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
Financial updatesPharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2023 (the “Period”).
Pharming Group reports fourth quarter and full year 2023 financial results
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2023.
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
Financial updatesExpect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end
Pharming Group reports third quarter 2023 financial results
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2023.
Pharming Group to report third quarter 2023 financial results on October 26
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.
Pharming Group to convene Extraordinary General Meeting of Shareholders
Financial updatesPharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST.
Pharming Group reports second quarter and first half 2023 financial results
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.
Pharming Group to report second quarter and first half 2023 financial results on August 3
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.
Pharming announces sale of priority review voucher
Financial updatesPharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. (“Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.